Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(alvimopan)
234 results
  • Postoperative Ileus. [Review]
    Clin Colon Rectal Surg. 2019 May; 32(3):166-170.Harnsberger CR, Maykel JA, Alavi K
  • Postoperative ileus (POI) is a common complication following colon and rectal surgery, with reported incidence ranging from 10 to 30%. It can lead to increased morbidity, cost, and length of stay. Although definitions vary considerably in the literature, in its pathologic form, it can be characterized by a temporary inhibition of gastrointestinal motility after surgical intervention due to nonmec…
  • New developments in the treatment of opioid-induced gastrointestinal symptoms. [Review]
    United European Gastroenterol J. 2018 Oct; 6(8):1126-1135.Pannemans J, Vanuytsel T, Tack J
  • Chronic pain affects a large part of the global population, leading to an increase of opioid use. Opioid-induced constipation (OIC), a highly prevalent adverse effect of opioid use, has a major impact on patients' quality of life. Thanks to the introduction of new drugs for chronic constipation, which can also be used in OIC, and the development of peripherally acting mu-opioid receptor blockers,…
  • Alvimopan usage increasing following radical cystectomy. [Journal Article]
    World J Urol. 2019 Jun; 37(6):1151-1155.Belle JD, Pooli A, … Deibert CM
  • CONCLUSIONS: This study, the largest to examine the real-world utilization of alvimopan since FDA approval for RC, shows that alvimopan utilization has increased substantially and is associated with reduced perioperative morbidity in patients undergoing cystectomy.
  • Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care. [Review]
    Cochrane Database Syst Rev. 2018 06 05; 6:CD006332.Candy B, Jones L, … Stone P
  • CONCLUSIONS: In this update, the conclusions for naldemedine are new. There is moderate-quality evidence to suggest that, taken orally, naldemedine improves bowel function over two weeks in people with cancer and OIBD but increases the risk of adverse events. The conclusions on naloxone and methylnaltrexone have not changed. The trials on naloxone did not assess laxation at 24 hours or over two weeks. There is moderate-quality evidence that methylnaltrexone improves bowel function in people receiving palliative care in the short term and over two weeks, and low-quality evidence that it does not increase adverse events. There is a need for more trials including more evaluation of adverse events. None of the current trials evaluated effects in children.
New Search Next